Cancer therapy with DNA-based vaccines

Immunology Letters

Volumn 74, Issue 1, 2000, Pages 59-65

  Cohen, Edward P ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

DNA based vaccines; Genotype; Immunotherapeutic properties

Indexed keywords

CANCER VACCINE; DNA VACCINE; HYGROMYCIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; DNA TRANSFECTION; FIBROBLAST; HUMAN; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0034666404     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(00)00250-9     Document Type: Article

References (36)

1. Anichini A., Mortarini R., Maccall C., Squarcina P., Fleischhauer K., Mascheroni L., Parmiani G. Cytoxic T cells directed to tumor antigens not expressed on normal malanocytes dominate HLA-A2. 1-restricted immune repetoire to melanoma. J. Immunol. 156:1996;208-217.
2. Boon T., Cerottine J.-C., vandenEynde B., vanderBruggen P., vanPel A. Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol. 12:1994;337-360.
3. Boon T., vanderBruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:1996;725-729.
4. Bronner C., Baker S., Morrison P., Warren G., Smith L., Lescoe M., Kane M., Earabino C., Lipford J., Lindbloom A., Tannergard P., Bollag R., Godwin A., Ward D., Nordenskjold M., Fishel R., Kolodner R., Liskay M. Mutation in the DNA mismatch repair gene homologue hMLH is associated with hereditary non-polyposis colon cancer. Nature. 368:1994;258-261.
5. Carr-Brendel V., Markovic D., Ferrer K., Smith M., Taylor-Papadimitriou J., Cohen E.P., 1998. Development of Immunity to Murine Breast Cancer Cells modified to express MUC-1, a Human brest Cancer antigen, in transgenic mice tolerant to human MUC-1, Cancer Rewsearch, in press.
6. deZoeten E.F., carr-Brendel V., Cohen E.P. Resistance to melanoma in mice immunized with semi-allogeneic fibroblasts transfected with genomic DNA from melanoma cells. J. Immunol. 160:1998;2915-2922.
7. deZoeten E.F., Carr-Brendel V., Markovic D., Taylor-Papadimitriou J., Cohen E.P. Immunity to breast cancer in mice immunized with semi-allogeneic fibroblasts transfected with DNA from breastr cancer cells. J. Immunol. 162:1999;6934-6941.
8. Fishel F., Lescoe M.K., Rao M.R.S., Copeland N.G., Jenkins N.A., Garber J., Kane M., Kolodner R. The human mutator gene homolog MSH2 and its association with herditary nonpolyposis colon cancer. Cell. 75:1993;1027-1038.
9. Folkman J. Incipient angiogenesis. Natl. Cancer Inst. 92:2000;94-101.
10. Futreal P., Soderkvist P., Marks J., Iglehart J., Cochrn C., Barrett J., Wiseman R. Detection of frequent allelic loss on proximal chromosone 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res. 52:1992;2624-2627.
11. Gonzalez-Zulueta M., Ruppert J.M., Tokino K., Tsai Y.C., SpruckIII C.H., Miyao N., Nichols P.W., Hermann G.G., Horn T., Steven K., Summerhayes I.C., Sidransky D., Jones P.A. Microsatellite instability in bladder cancer. Cancer Res. 53:1993;5620-5623.
12. Hahnfeldt P., Panigrahy D., Folkman J., Hlatky L. Tumor development under angiogenic signaling: a dynamicical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59:1999;4770-4775.
13. Jerome K.R., Barnd D.L., Bendt K.M., Boyer C.M., Taylor-Papadimitriou J., McKenzie I.F.C., Bast R.C., Finn O.J. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:1991;2908-2916.
14. Kim B.S., Cohen E.P. Tumor specific immunity induced by some somatic hybridsI: lack of relationship between immunogenicity and tumorigenicity of selected hybrids. J. Immunol. 123:1979;733-738.
15. Kolchinsky A., Roninson I.B. Drug resistance conferred by MDRI expression in spheroids formed by glioblastoma cell lines. Anticancer Res. 17:1997;3321-3327.
16. Gendler S., Cohen E., Craston A., Duhig T., Johnstone G., Barnes D. The locus of the Poymorphic Epithelial mucin (PEM) tumor antigen on chromosone 1q21 shows a high frequency of alteration in primary human breast tumors. Int. J. Cancer. 45:1990;431-435.
17. Gilboa E. The makings of a tumor rejection antigen. Immunity. 11:1999;263-270.
18. Gilboa E., Nair S.K., Lyerly H.K. Immunotherapy of cancer with dendritic cell-based vaccines. Cancer Immunol. Immunother. 46:1998;82-87.
19. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:1997;558-561.
20. Kavathas P., Herzenberg L.A. stable transformation of mouse LM cells (a transformed fibroblast line) for human membrane T cell differentiation antigens, HLA and B2 microglobin: selection by flouresence-axctivated cell sorting. Proc. Natl. Acad. Sci. (USA). 80:1983;524-528.
21. Hsu C., Kavathas P., Herzenberg L.A. Cell surface antigens expressed on L cells tramsfected with whole DNA from non-expressing and expressing cells. Nature. 312:1984;68-69.
22. Liang W., Cohen E.P. Resistance to murine leukemia in mice rejecting syngeneic somatic hybrid cells. J. Immunol. 116:1975a;623-629.
23. Liang W., Cohen E.P. Resistance to urine leukemia in mice receiving simultaneous injections of syngeneic hybrid and neoplastic cells. J. Immunol. 118:1977b;903-909.
24. Lotze M.T. Getting to the source: denritic cells as therapeutic agents for the treatment of cancer patients. Ann. Surg. 226:1997;1-5.
25. Mendersohn C., Johnson B., Lionetti K.A., Nobis P., Wimmer E., Racaniello V.R. Transformation of a human poliovirus receptor gene into mouse cells. Proc. Natl. Acad. Sci. (USA). 83:1986;7845-7849.
26. Miles D.W., Taylor-Papadimitriou J. Mucin-based breast cancer vaccines. Expert. Opin. Invest. Drugs. 7:1998;1865-1871.
27. Prehn R.T., Main J. Immunitry to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:1957;769-794.
28. Risinger J.I., Berchuck A., Kohler M.F., Watson P., Lynch H.T., Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res. 53:1993;5100-5103.
29. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:1999;281-287.
30. Shigemasa K., Tanimoto H., Sakata K., Nagai N., Parmley T.H., Ohama K., O'Brien T.J. Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med. Oncol. 17:2000;52-58.
31. Shih C., Weinberg R. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell. 29:1982;161-169.
32. Sun T., Kim T.S., Waltz M.R., Cohen E.P. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice. Cancer Gene Ther. 2:1995;183-190.
33. Thibodeau S., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 260:1993;816-819.
34. Thompson A., Morris R., Wallace M., Wylie A., Steele C., Carter D. Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC expression in breast cancer. Brit. J. Cancer. 68:1993;64-68.
35. VanPel A., Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl. Acad. Sci. USA. 79:1982;4718-4722.
36. Wigler M., Pellicer A., Silverstein S., Axel R., Urlaub O., Chasm L. DNA-mediated transfer of the adenine phosphoribosyltransferase locusinto mammalian cells. Proc. Natl. Acad. Sci. (USA). 76:1979;1373-1376.